Waltham, Mass.-based biotechnology company Radius Health Inc. appointed Charles Morris as chief medical officer.
Morris was previously chief development officer at PsiOxus Therapeutics Ltd. He has also worked as the chief medical officer at Allos Therapeutics Inc., where he focused on the development of Folotyn in hematologic and solid tumors.
Jesper Hoiland, president and CEO of Radius Health, said that Morris' experience of late-stage drug trials and regulatory approvals will be vital during the phase 3 study of Elacestrant, or RAD1901, a treatment for breast cancer.
Radius Health develops hormone-based treatments for bone diseases and cancer.